Benitec Ltd (BNIKF) 0.3300 $BNIKF
Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu Sep 24, 9:00AM CDT
What:
BNTC: 6.75 (-0.10), BNTCW: 2.40 (-0.09), NDAQ: 53.09 (-0.69), BLT: 6.83 (+0.09)
Benitec Featured at CHI's "Discovery On Target" Conference
PR Newswire - Wed Sep 23, 7:00AM CDT
Benitec Biopharma (ASX: BLT; NASDAQ: BNTCW, NASDAQ: BNTC), a clinical-stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), today announced that Peter French, Ph.D., the Company's CEO and Managing Director, was invited to discuss Benitec's ddRNAi technology at The Cambridge Healthtech Institute's (CHI) 13th Annual Discovery on Target Conference in Boston, MA.
Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial
PR Newswire - Wed Sep 16, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT) a clinical-stage biotechnology company developing innovative therapeutics based on its gene-silencing technology, DNA-directed RNA interference (ddRNAi), is pleased to announce it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas. The site has commenced pre-screening hepatitis C patients and is led by principal investigator Dr. Parvez Mantry, a gastroenterologist and hepatologist.
Non-Small Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Thu Sep 10, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lckl3z/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 200 companies mentioned in this comprehensive report: - AB Science - Bayer AG - Benitec Biopharma - Calithera Biosciences - Daiichi Sankyo - Eagle Pharmaceuticals - F. Hoffmann-La Roche - Five Prime Therapeutics - GeneFrontier - Halozyme Therapeutics - HanAll Biopharma - Ignyta - Immune Design - Jeil Pharmaceutical - Jiangsu Hengrui Medicine - Kadmon - KAEL-GemVax - Mabion - MacroGenics - NanoCarrier - Natco Pharma - Omnitura Therapeutics - Oncobiologics - Panacea Biotec - Peregrine Pharmaceuticals - Qu Biologics - Reata Pharmaceuticals - Samyang - Sanofi - Taiho Pharmaceutical - Targovax - Ultimovacs - XBiotech USA - Zhejiang BetaPharma For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/lc...small_cell
IMDZ: 12.24 (+0.25), CALA: 7.61 (+0.09), EGRX: 68.06 (+1.79), FPRX: 15.48 (-0.04)
Benitec Announces Closing Of An Initial Public Offering In The United States With Listing On NASDAQ
PR Newswire - Mon Aug 24, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT), a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs)1, representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares. Each ADS represents 20 ordinary shares of Benitec. Benitec has granted the underwriter a 45-day option to purchase up to an additional 225,000 ADSs and/or 75,000 warrants to purchase ADSs to cover over-allotments, if any. Simultaneously with the closing, Benitec issued and sold 75,000 warrants in connection with the underwriter's partial exercise of such option.
Benitec Announces Pricing Of An Initial Public Offering In The United States With Listing On NASDAQ
PR Newswire - Tue Aug 18, 7:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT), a clinical-stage biotechnology company, is pleased to announce the pricing of its U.S. initial public offering of 1,500,000 American Depositary Shares[1] (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec and warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares, at a price of US$9.21 per ADS and US$0.01 per warrant. Each ADS represents 20 ordinary shares of Benitec. The warrants will have a per ADS exercise price of US$5.50, are exercisable immediately and will expire on August 21, 2020. Benitec has granted the underwriters a 45-day option to purchase up to an additional 225,000 ADSs and/or 75,000 warrants to purchase ADSs to cover over-allotments, if any.
Hepatitis B - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hepatitis B
M2 - Mon Aug 17, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvqbsr/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information Key Topics Covered: - Introduction - Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Abivax S.A. - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - AltraVax Inc. - Amarna Therapeutics B.V. - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - Big DNA Ltd. - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cytos Biotechnology AG - Dynavax Technologies Corporation For more information visit http://www.researchandmarkets.com/research/vv...epatitis_b
DVAX: 23.86 (+0.39), BSPM: 0.72 (+0.02), CMRX: 37.40 (-0.19), ARWR: 5.89 (+0.13), ASMB: 10.87 (+1.14)
Cancer Pain Therapeutics Pipeline Review, H1 2015 - 28 Companies & 34 Drug Profiles
M2 - Fri Jul 31, 8:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sbhbp/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Grunenthal GmbH - GW Pharmaceuticals Plc - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Nippon Kayaku Co., Ltd. - Northern Light Pharmaceuticals AB - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - Recordati S.p.A. - Sorrento Therapeutics, Inc. - Virobay Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - AMS-410 ER12 - ANG-2002 - BBI-11008 - calpastatin - cebranopadol - crotalphine - DD-04107 - dexmedetomidine hydrochloride - dronabinol - Drug for Cancer Neuropathic Pain - fentanyl - fentanyl citrate - fulranumab - HS-198 - hydromorphone hydrochloride - INT-0028 - IPP-102199 - ketamine hydrochloride ER - KLS-2010 - methadone hydrochloride - nabiximols - Nervarna - NKTR-192 - Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - PGN-202 - PL-265 - Q-201 - QX-314 - resiniferatoxin - saracatinib difumarate - Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule to Antagonize Chemokine Receptor for Cancer Pain For more information visit http://www.researchandmarkets.com/research/5s...ancer_pain
BDSI: 6.74 (+0.22), PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), SRNE: 8.61 (+0.05), ZYNE: 14.38 (-0.14), NKTR: 11.34 (+0.56), AZN: 32.23 (-0.16), VBAY: (), PTIE: 1.99 (+0.02)
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board
PR Newswire - Wed Jul 22, 6:00AM CDT
Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief Executive until a permanent appointment is made.
NVGN: 2.66 (-0.03)
Muscular Dystrophy Pipeline Report 2015 - 21 Companies & 47 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89rk9v/muscular) has announced the addition of the "Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - aTyr Pharma, Inc. - Benitec Biopharma Limited - Bioblast Pharma Ltd. - BioMarin Pharmaceutical Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Fate Therapeutics, Inc. - Genethon - Genzyme Corporation - Isis Pharmaceuticals, Inc. - Marina Biotech, Inc. - Novogen Limited - PolyNovo Limited - Prothelia, Inc. - SanBio, Inc. - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Valentia Biopharma S.L. For more information visit http://www.researchandmarkets.com/research/89rk9v/muscular
FATE: 5.67 (+0.17), BMRN: 102.69 (+1.97), ISIS: 43.24 (+0.86), SRPT: 37.09 (-0.72), XLRN: 24.08 (-0.18)
Dry (Atrophic) Macular Degeneration Therapeutics Pipeline Review, H1 2015 - 20 Companies & 29 Drug Profiles
M2 - Thu Jul 09, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d36tg9/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Bioheart, Inc. - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Eleven Biotherapeutics Inc. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AdipoCell - APL-2 - avacincaptad pegol sodium - EBI-028 - eculizumab - emixustat hydrochloride - fluocinolone acetonide - Gene Therapy for Ocular Diseases - GS-020 - GSK-933776 - HMR-59 - ICR-14967 - lampalizumab - MA09-hRPE - MC-1101 - methotrexate - minocycline Gel - NM-9405 - NT-501 - OpRegen - OpRegen Plus - RC-1 Alpha - Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - RST-001 - Small Molecules for Age Related Macular Degeneration - Small Molecules for AMD - Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - TT-231 For more information visit http://www.researchandmarkets.com/research/d3...y_atrophic
OCAT: 4.70 (+0.02), OPHT: 42.73 (+0.20), FOMX: 6.84 (+0.17), GSK: 40.22 (+0.06), ALIM: 2.61 (+0.04), ALXN: 161.08 (-3.23)
Benitec Acquires Full Rights To Hepatitis B Program
PR Newswire - Thu Jul 09, 6:15AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) and China-based Biomics Biotechnologies are pleased to announce Benitec has acquired the full rights to the pre-clinical ddRNAi-based Hepatitis B (HBV) therapeutic program, Hepbarna(TM), which was previously under development as a joint venture between the two companies.
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 88.80 (+0.30), DRNA: 10.05 (+0.88), ALNY: 83.16 (+0.88), TKMR: 10.83 (+0.58), JUNO: 48.64 (+0.84), CELG: 117.38 (-0.59)
PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis of the 20 Leading Biotech Companies
M2 - Thu Jul 02, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfrgdp/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" company profile to their offering. "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" report is an essential source of information and analysis on the gene therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends analysis, The publisher provides an in-depth analysis of the current and future growth drivers of the gene therapy market. The report discusses the key factors shaping and driving the gene therapy business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of gene therapies. Key Questions Answered - What are the drivers of the gene therapy field? - Who are the leading companies involved in the development of gene therapies? - What are the major trends in gene therapy clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What progress has been made in terms of viral vector technology and gene delivery? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the gene therapy field? Scope - This report provides market developments across the gene therapy field, including clinical trials, deals, and pipeline investments - Investment examined on both the industry and financial communities - Broad discussion on the science behind gene therapies, viral vectors, and gene delivery - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activity - Deals activity examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 20 leading biotech companies developing gene therapies Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Gene Therapy Overview 4 Market Developments 5 Clinical Trials 6 Company Analysis 7 Deals Landscape 8 Strategic Outlook 9 Appendix Companies Mentioned - Advantagene - ALS Therapy Development Institute - Amarna Therapeutics - American Gene Technologies - AnGes MG - Applied Genetic Technologies International - Asklepios BioPharmaceutical - Avalanche Biotechnologies - Benitec BioPharma - Bluebird bio - Celladon - Cellectis - CFR Pharmaceuticals - Chiesi Farmaceutici - Dimension Therapeutics - GeneCure Biotechnologies - Genethon - GenSight Biologics - InoCard - Oxford BioMedica - Proximagen - ReGenX Biosciences - Sangamo BioSciences - Spark Therapeutics - Tacere Therapeutics - TransgeneTransposagen - UniQure - Voyager Therapeutics For more information visit http://www.researchandmarkets.com/research/rf...armasphere
ONCE: 49.30 (+1.86), SGMO: 5.94 (+0.38), AAVL: 8.48 (+0.01)
Biotech Investors Should Read Bibliographies Of Chief Scientific Officers
Intrepid Investor - at Seeking Alpha - Tue Jun 30, 11:42AM CDT
BLUE: 88.80 (+0.30), BIIB: 269.16 (-10.72), TBIO: 0.92 (-0.02), SGMO: 5.94 (+0.38), SRNE: 8.61 (+0.05), CELG: 117.38 (-0.59), VICL: 0.43 (unch), GILD: 100.65 (-0.16), SGEN: 39.38 (+0.87), AEZS: 0.09 (unch), REGN: 503.92 (+12.71)
Benitec Biopharma Limited - Product Pipeline Review - 2014
M2 - Tue Jun 09, 7:54AM CDT
Product Pipeline Review - 2014
Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial
PR Newswire - Wed Apr 29, 6:05AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit. The fifth patient is the third and final patient to be dosed in Cohort 2.
Asklepios Executes License with Benitec
Business Wire - Thu Apr 16, 12:34PM CDT
Benitec Biopharma and Asklepios BioPharmaceutical, Inc. (AskBio) have announced entering into a broad license agreement, granting Benitec rights to AskBio's proprietary platform gene therapy technologies. AskBio's Adeno-Associated Virus (AAV) gene therapy technologies are currently being used in Benitec's phase I/II first-in-man trial, to evaluate the safety and efficacy of its experimental therapy (TT-034), for the treatment of Hepatitis C (HCV). HCV is the most common chronic blood-borne infection in the United States, and is the leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer.
Benitec Provides Update On TT-034 Trial
PR Newswire - Tue Apr 07, 6:11AM CDT
Benitec Biopharma (ASX:BLT; OTCPK:BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that laboratory results from liver biopsies in the company's 'first in man', Phase I/IIa clinical trial of TT-034 for hepatitis C confirmed that the trial is proceeding according to expectations.
Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu Sep 24, 9:00AM CDT
What:
BNTC: 6.75 (-0.10), BNTCW: 2.40 (-0.09), NDAQ: 53.09 (-0.69), BLT: 6.83 (+0.09)
Benitec Featured at CHI's "Discovery On Target" Conference
PR Newswire - Wed Sep 23, 7:00AM CDT
Benitec Biopharma (ASX: BLT; NASDAQ: BNTCW, NASDAQ: BNTC), a clinical-stage biotechnology company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), today announced that Peter French, Ph.D., the Company's CEO and Managing Director, was invited to discuss Benitec's ddRNAi technology at The Cambridge Healthtech Institute's (CHI) 13th Annual Discovery on Target Conference in Boston, MA.
Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial
PR Newswire - Wed Sep 16, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT) a clinical-stage biotechnology company developing innovative therapeutics based on its gene-silencing technology, DNA-directed RNA interference (ddRNAi), is pleased to announce it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas. The site has commenced pre-screening hepatitis C patients and is led by principal investigator Dr. Parvez Mantry, a gastroenterologist and hepatologist.
Non-Small Cell Lung Cancer - Pipeline Review, H1 2015
M2 - Thu Sep 10, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lckl3z/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 200 companies mentioned in this comprehensive report: - AB Science - Bayer AG - Benitec Biopharma - Calithera Biosciences - Daiichi Sankyo - Eagle Pharmaceuticals - F. Hoffmann-La Roche - Five Prime Therapeutics - GeneFrontier - Halozyme Therapeutics - HanAll Biopharma - Ignyta - Immune Design - Jeil Pharmaceutical - Jiangsu Hengrui Medicine - Kadmon - KAEL-GemVax - Mabion - MacroGenics - NanoCarrier - Natco Pharma - Omnitura Therapeutics - Oncobiologics - Panacea Biotec - Peregrine Pharmaceuticals - Qu Biologics - Reata Pharmaceuticals - Samyang - Sanofi - Taiho Pharmaceutical - Targovax - Ultimovacs - XBiotech USA - Zhejiang BetaPharma For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/lc...small_cell
IMDZ: 12.24 (+0.25), CALA: 7.61 (+0.09), EGRX: 68.06 (+1.79), FPRX: 15.48 (-0.04)
Benitec Announces Closing Of An Initial Public Offering In The United States With Listing On NASDAQ
PR Newswire - Mon Aug 24, 6:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT), a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs)1, representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares. Each ADS represents 20 ordinary shares of Benitec. Benitec has granted the underwriter a 45-day option to purchase up to an additional 225,000 ADSs and/or 75,000 warrants to purchase ADSs to cover over-allotments, if any. Simultaneously with the closing, Benitec issued and sold 75,000 warrants in connection with the underwriter's partial exercise of such option.
Benitec Announces Pricing Of An Initial Public Offering In The United States With Listing On NASDAQ
PR Newswire - Tue Aug 18, 7:30AM CDT
Benitec Biopharma Limited (NASDAQ: BNTC; NASDAQ: BNTCW; ASX: BLT), a clinical-stage biotechnology company, is pleased to announce the pricing of its U.S. initial public offering of 1,500,000 American Depositary Shares[1] (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec and warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares, at a price of US$9.21 per ADS and US$0.01 per warrant. Each ADS represents 20 ordinary shares of Benitec. The warrants will have a per ADS exercise price of US$5.50, are exercisable immediately and will expire on August 21, 2020. Benitec has granted the underwriters a 45-day option to purchase up to an additional 225,000 ADSs and/or 75,000 warrants to purchase ADSs to cover over-allotments, if any.
Hepatitis B - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hepatitis B
M2 - Mon Aug 17, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvqbsr/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information Key Topics Covered: - Introduction - Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Abivax S.A. - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - AlphaMab Co., Ltd - AltraVax Inc. - Amarna Therapeutics B.V. - Arrowhead Research Corporation - Assembly Biosciences, Inc. - Beijing Minhai Biotechnology Co., Ltd - Benitec Biopharma Limited - Big DNA Ltd. - BioDiem Ltd - Biogenomics Limited - Biological E. Limited - BioStar Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Bukwang Pharm.Co., Ltd. - Celltrion, Inc. - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - ChronTech Pharma AB - Cytos Biotechnology AG - Dynavax Technologies Corporation For more information visit http://www.researchandmarkets.com/research/vv...epatitis_b
DVAX: 23.86 (+0.39), BSPM: 0.72 (+0.02), CMRX: 37.40 (-0.19), ARWR: 5.89 (+0.13), ASMB: 10.87 (+1.14)
Cancer Pain Therapeutics Pipeline Review, H1 2015 - 28 Companies & 34 Drug Profiles
M2 - Fri Jul 31, 8:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sbhbp/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Grunenthal GmbH - GW Pharmaceuticals Plc - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Nippon Kayaku Co., Ltd. - Northern Light Pharmaceuticals AB - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - Recordati S.p.A. - Sorrento Therapeutics, Inc. - Virobay Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - AMS-410 ER12 - ANG-2002 - BBI-11008 - calpastatin - cebranopadol - crotalphine - DD-04107 - dexmedetomidine hydrochloride - dronabinol - Drug for Cancer Neuropathic Pain - fentanyl - fentanyl citrate - fulranumab - HS-198 - hydromorphone hydrochloride - INT-0028 - IPP-102199 - ketamine hydrochloride ER - KLS-2010 - methadone hydrochloride - nabiximols - Nervarna - NKTR-192 - Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - PGN-202 - PL-265 - Q-201 - QX-314 - resiniferatoxin - saracatinib difumarate - Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule to Antagonize Chemokine Receptor for Cancer Pain For more information visit http://www.researchandmarkets.com/research/5s...ancer_pain
BDSI: 6.74 (+0.22), PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), SRNE: 8.61 (+0.05), ZYNE: 14.38 (-0.14), NKTR: 11.34 (+0.56), AZN: 32.23 (-0.16), VBAY: (), PTIE: 1.99 (+0.02)
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board
PR Newswire - Wed Jul 22, 6:00AM CDT
Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief Executive until a permanent appointment is made.
NVGN: 2.66 (-0.03)
Muscular Dystrophy Pipeline Report 2015 - 21 Companies & 47 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89rk9v/muscular) has announced the addition of the "Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - aTyr Pharma, Inc. - Benitec Biopharma Limited - Bioblast Pharma Ltd. - BioMarin Pharmaceutical Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Fate Therapeutics, Inc. - Genethon - Genzyme Corporation - Isis Pharmaceuticals, Inc. - Marina Biotech, Inc. - Novogen Limited - PolyNovo Limited - Prothelia, Inc. - SanBio, Inc. - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Valentia Biopharma S.L. For more information visit http://www.researchandmarkets.com/research/89rk9v/muscular
FATE: 5.67 (+0.17), BMRN: 102.69 (+1.97), ISIS: 43.24 (+0.86), SRPT: 37.09 (-0.72), XLRN: 24.08 (-0.18)
Dry (Atrophic) Macular Degeneration Therapeutics Pipeline Review, H1 2015 - 20 Companies & 29 Drug Profiles
M2 - Thu Jul 09, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d36tg9/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Bioheart, Inc. - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Eleven Biotherapeutics Inc. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AdipoCell - APL-2 - avacincaptad pegol sodium - EBI-028 - eculizumab - emixustat hydrochloride - fluocinolone acetonide - Gene Therapy for Ocular Diseases - GS-020 - GSK-933776 - HMR-59 - ICR-14967 - lampalizumab - MA09-hRPE - MC-1101 - methotrexate - minocycline Gel - NM-9405 - NT-501 - OpRegen - OpRegen Plus - RC-1 Alpha - Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - RST-001 - Small Molecules for Age Related Macular Degeneration - Small Molecules for AMD - Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - TT-231 For more information visit http://www.researchandmarkets.com/research/d3...y_atrophic
OCAT: 4.70 (+0.02), OPHT: 42.73 (+0.20), FOMX: 6.84 (+0.17), GSK: 40.22 (+0.06), ALIM: 2.61 (+0.04), ALXN: 161.08 (-3.23)
Benitec Acquires Full Rights To Hepatitis B Program
PR Newswire - Thu Jul 09, 6:15AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) and China-based Biomics Biotechnologies are pleased to announce Benitec has acquired the full rights to the pre-clinical ddRNAi-based Hepatitis B (HBV) therapeutic program, Hepbarna(TM), which was previously under development as a joint venture between the two companies.
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 88.80 (+0.30), DRNA: 10.05 (+0.88), ALNY: 83.16 (+0.88), TKMR: 10.83 (+0.58), JUNO: 48.64 (+0.84), CELG: 117.38 (-0.59)
PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis of the 20 Leading Biotech Companies
M2 - Thu Jul 02, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfrgdp/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" company profile to their offering. "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" report is an essential source of information and analysis on the gene therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends analysis, The publisher provides an in-depth analysis of the current and future growth drivers of the gene therapy market. The report discusses the key factors shaping and driving the gene therapy business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of gene therapies. Key Questions Answered - What are the drivers of the gene therapy field? - Who are the leading companies involved in the development of gene therapies? - What are the major trends in gene therapy clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What progress has been made in terms of viral vector technology and gene delivery? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the gene therapy field? Scope - This report provides market developments across the gene therapy field, including clinical trials, deals, and pipeline investments - Investment examined on both the industry and financial communities - Broad discussion on the science behind gene therapies, viral vectors, and gene delivery - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activity - Deals activity examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 20 leading biotech companies developing gene therapies Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Gene Therapy Overview 4 Market Developments 5 Clinical Trials 6 Company Analysis 7 Deals Landscape 8 Strategic Outlook 9 Appendix Companies Mentioned - Advantagene - ALS Therapy Development Institute - Amarna Therapeutics - American Gene Technologies - AnGes MG - Applied Genetic Technologies International - Asklepios BioPharmaceutical - Avalanche Biotechnologies - Benitec BioPharma - Bluebird bio - Celladon - Cellectis - CFR Pharmaceuticals - Chiesi Farmaceutici - Dimension Therapeutics - GeneCure Biotechnologies - Genethon - GenSight Biologics - InoCard - Oxford BioMedica - Proximagen - ReGenX Biosciences - Sangamo BioSciences - Spark Therapeutics - Tacere Therapeutics - TransgeneTransposagen - UniQure - Voyager Therapeutics For more information visit http://www.researchandmarkets.com/research/rf...armasphere
ONCE: 49.30 (+1.86), SGMO: 5.94 (+0.38), AAVL: 8.48 (+0.01)
Biotech Investors Should Read Bibliographies Of Chief Scientific Officers
Intrepid Investor - at Seeking Alpha - Tue Jun 30, 11:42AM CDT
BLUE: 88.80 (+0.30), BIIB: 269.16 (-10.72), TBIO: 0.92 (-0.02), SGMO: 5.94 (+0.38), SRNE: 8.61 (+0.05), CELG: 117.38 (-0.59), VICL: 0.43 (unch), GILD: 100.65 (-0.16), SGEN: 39.38 (+0.87), AEZS: 0.09 (unch), REGN: 503.92 (+12.71)
Benitec Biopharma Limited - Product Pipeline Review - 2014
M2 - Tue Jun 09, 7:54AM CDT
Product Pipeline Review - 2014
Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial
PR Newswire - Wed Apr 29, 6:05AM CDT
Benitec Biopharma (ASX: BLT; OTCPK: BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit. The fifth patient is the third and final patient to be dosed in Cohort 2.
Asklepios Executes License with Benitec
Business Wire - Thu Apr 16, 12:34PM CDT
Benitec Biopharma and Asklepios BioPharmaceutical, Inc. (AskBio) have announced entering into a broad license agreement, granting Benitec rights to AskBio's proprietary platform gene therapy technologies. AskBio's Adeno-Associated Virus (AAV) gene therapy technologies are currently being used in Benitec's phase I/II first-in-man trial, to evaluate the safety and efficacy of its experimental therapy (TT-034), for the treatment of Hepatitis C (HCV). HCV is the most common chronic blood-borne infection in the United States, and is the leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer.
Benitec Provides Update On TT-034 Trial
PR Newswire - Tue Apr 07, 6:11AM CDT
Benitec Biopharma (ASX:BLT; OTCPK:BTEBY), a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that laboratory results from liver biopsies in the company's 'first in man', Phase I/IIa clinical trial of TT-034 for hepatitis C confirmed that the trial is proceeding according to expectations.
